Kornimate/medical-research-clean huggingface dataset:
doripenem in the treatment of hospital-acquired pneumonia

Conditions: Pneumonia

Summary: the purpose of this study is to compare the safety and effectiveness of doripenem in patients with hospital-acquired pneumonia (hap).

doripenem is an antibiotic medication not yet approved by the us fda. this is a phase 3, multicenter, prospective, open-label (though with blinded outcome assessments), randomized study of doripenem versus a comparator antibiotic in patients with hospital-acquired pneumonia. the study consists of screening phase, open-label treatment phase, and follow-up. both patients on ventilator and not on ventilator are enrolled. the primary endpoint is the clinical response rate at early follow-up visit. the patients may receive either doripenem or comparator; total duration of the treatment is 7 to 14 days.

Eligibility criteria:
inclusion criteria: * patients hospitalized for \>= 48 hours or those with prior hospital admission of at least 48 hours who were discharged within the last 48 hours. exclusion criteria: * hospital-acquired pneumonia known at the time of enrollment to be caused by pathogen(s) resistant to certain antibiotics * any rapidly progressing disease or immediately life-threatening illness

Keywords: hospital-acquired pneumonia mechanical ventilation
the"fuzheng" therapy of tcm to improve the survival quality of early-stage nsclc by intervening the ctcs

Conditions: Non-small Cell Lung Cancer(NSCLC)

Summary: metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells(ctcs) play a key role in the process of distant metastasis. the investigators' study will elaborate the clinical significance of ctcs intervented by traditional chinese medicine(tcm) in lung cancer from the diagnosis and clinical staging,metastasis and recurrence, individual treatment and prognosis and so on, in order to provide a new direction for the treatment of lung cancer.

metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells play a key role in the process of distant metastasis.in recent years, research results have shown that ctcs may become a emerging marker and new target in the treatment of lung cancer. the investigators' study will elaborate the clinical significance of ctcs intervented by tcm in lung cancer from the diagnosis and clinical staging,metastasis and recurrence, individual treatment and prognosis and so on, in order to provide a new direction for the treatment of lung cancer.

Eligibility criteria:
inclusion criteria: 1. complete resection was accepted in iia \~ ⅲa stage, and the pathological changes could confirmed as non small cell lung cancer patients; 2. patients receiving chemotherapy for the first time in 6 weeks after surgery; 3. age from 18 years to 70 years; 4. the liver and renal function were normal,and no other disease. 5. patients compliance is good ang can understand the situation of this study and signed informed consent exclusion criteria: 1. patients without clear pathological diagnosis; 2. the expected survival period is morn than 6 months; 3. patients with serious diseases such as heart, liver, kidney and hematopoietic system; 4. patients with pregnancy or lactation; 5. persons with a history of less control.

Keywords: circulating tumor cells(ctcs) traditional chinese medicine(tcm) myeloid-derived suppressor cells(mdscs)
fentanyl matrix application for cancer pain: multicenter, prospective, observational study

Conditions: Pain

Summary: the purpose of this study is to show the clinical usefulness of fentanyl matrix by measuring satisfaction with pain treatment after administering fentanyl matrix in patients whose pain was not controlled sufficiently with the previous analgesic use in real practice at the investigator's discretion.

this is a multi-center, open-label (all people know the identity of the intervention), prospective (the patients are identified and then followed forward in time for the outcome of the study) observational study. the study population comprises patients who are admitted to a study center during the study period and are receiving a strong oral long-acting opioid analgesic but deemed to control pain insufficiently. since this study is an observational study conducted in real practice, a dose of fentanyl matrix should be adjusted depending on an individual patient's response at the investigator's discretion. however, for the patients whose pain is not sufficiently controlled despite administration of strong long-acting opioid analgesics, the minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust dosage according to the degree of the patients' pain control during the 9 days of the study period.

Eligibility criteria:
inclusion criteria: * patients complaining of cancer pain which requires administration of long-acting opioid analgesics * patients whose pain is not sufficiently controlled despite administration of strong long-acting opioid analgesics * patients who are deemed to need an initial minimum dose of fentanyl matrix 75 micrograms/h * patients who signed the informed consent form exclusion criteria: * patients with a history of or current drug or alcohol abuse * childbearing women who are pregnant or likely to be pregnant during the study period and men who are neither infertile nor willing to refrain from sexual relations but whose partner does not conduct an effective contraception * patients who are unable to use a transdermal system due to skin disease * patients with history of hypersensitivity to opioid analgesics * patients who are not eligible for the study participation based on warnings, precautions and contraindications in the package insert of the study drug at the investigator's discretion

Keywords: pain cancer pain fentanyl fentanyl matrix opioid analgesic
the diet trial - dietetic intervention in psoriatic arthritis

Conditions: Arthritis, Psoriatic; Metabolic Syndrome

Summary: psoriasis (ps) and psoriatic arthritis (psa) are associated with increased risk of metabolic syndrome (mets), body fatness and cardiovascular risk. additionally, oxidative stress and inflammation are also contributing mechanisms on ps and psa. however, little is known about the influence of diet and micronutrients on the main outcomes of these diseases. the aim of the investigators is to evaluate the effectiveness of an intervention diet program on disease activity, metabolic profile and oxidative stress inpatients with psoriasis and psoriatic arthritis.


Eligibility criteria:
inclusion criteria: * patients with psoriatic arthritis, according to the classification criteria of psoriatic arthritis (caspar) exclusion criteria: * lack of written informed consent; * age \< 18 years old; * history of gastrointestinal, endocrine, pulmonary, kidney, hepatic, and neuromuscular diseases, as well as hiv-positive; * pregnant or breast-feeding women; * previous history of cancer; * use of steroids, protein supplements, vitamins, multivitamins, or antioxidants. * specific medications to psa and physical activity were required to be stable for the last 3 months to be included in the study

Keywords: psoriatic arthritis psoriasis body composition dxa measurements spondyloarthritis diet therapy adipose tissue
safety trial of nk cell dli 3-5/6 family member following nonmyeloablative asct

Conditions: Lymphoma

Summary: evaluate the safety of natural killer (nk) cell infusion using cd56 monoclonal antibody selected with miltenyi biotec system following nonmyeloablative stem cell transplantation (sct) from mismatched donors. this pilot study will evaluate toxicity including mortality, occurrence of acute graft versus host disease (agvhd) and other severe toxicity.

the use of non-selected donor lymphocyte infusions (dlis) (to help early immune recovery and induce antitumor response) following nonmyeloablative allogeneic stem cell transplantation (asct) is also complicated by the risk of acute graft versus host disease (agvhd) with 30-40% of patients experiencing grade iii-iv agvhd. data suggests that the use of natural killer (nk) cells (instead of nonselected dlis) in this setting may mediate a graft versus tumor (gvt) effect independently of agvhd. this pilot study is designed to evaluate the efficacy and toxicity of donor natural killer (nk) cell selection and infusion following nonmyeloablative allogeneic stem cell transplantation from mismatched donors.

Eligibility criteria:
inclusion criteria: * patients with who have undergone a non-myeloablative allogeneic transplant, using a 3-5/6 hla matched sibling donor. measureable disease is not needed at study entry. * performance status must be karnofsky 50-100%. * donor cellular engraftment of at least 2.5% from the non-myeloablative procedure. * ≤ grade 2 acute gvhd at time of infusion of nk cell infusion. patients with treated acute gvhd must be on a stable dose of therapy (no increase in immunosuppressive therapy for the 2 weeks before planned nki). the dosage/level of immunosuppressive therapy at the time of nki should be no greater than 1 mg/kg of prednisone daily or mycophenolate 1000 mg bid daily or cyclosporine with a target level of 200 or equivalent. * estimated survival at least 8 weeks. * age \> or equal to 18 years of age. exclusion criteria: * pregnant or lactating women, * patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance to this protocol. * patients who had biopsy proven overall grade 4 gvhd lasting longer than 7 days, from the non-myeloablative therapy, are not eligible

Keywords: stem cell transplant mismatched donor nk infusion
carbetocin versus oxytocin plus sublingual misoprostol in the management of atonic postpartum hemorrhage

Conditions: Postpartum Hemorrhage

Summary: the objective of this study is to compare the effectiveness and safety of carbetocin vs. oxytocin plus sublingual misoprostol in the management of atonic postpartum hemorrhage (pph)after vaginal delivery.

the first cause of hemorrhage at the time of delivery is uterine atony; therefore, there is general agreement that active management of the third stage of labor is recommended. oxytocin is the most widely used uterotonic agent but has a half-life of only 4-10 min, that is why it is better administered as a continuous intravenous infusion to achieve sustained uterotonic activity. carbetocin is a synthetic long-acting oxytocin agonistic analog with prolonged half-life prolonging its pharmacological effects. its prolonged uterine activity may theoretically offer advantages over oxytocin in the management of the third stage of labor. the side-effect profile of carbetocin was not found to be different from that of oxytocin but may prove to be advantageous when compared to syntometrine.

Eligibility criteria:
inclusion criteria: * all participants had pph defined as vaginal bleeding\>500 ml after vaginal delivery and uterine atony confirmed by abdominal palpation exclusion criteria: * gestational age\<37 weeks, * genital tract trauma, * coagulation defect, * women with hypertension, preeclampsia, cardiac, renal or liver diseases, epilepsy * known hypersensitivity to carbetocin or oxytocin.

Keywords: postpartum hemorrhage vaginal delivery carbetocin misoprostol oxytocin
randomized prospective study of selective laser trabeculoplasty (slt) versus argon trabeculoplasty (alt) in patients with pseudoexfoliation glaucoma and ocular hypertension

Conditions: Exfoliation Syndrome; Ocular Hypertension

Summary: multi-center, prospective, randomized, controlled clinical trial to compare selective laser trabeculoplasty (slt) and argon laser trabeculoplasty (alt) in pseudoexfoliation glaucoma and ocular hypertension patients. iop will be recorded, at baseline, 6 weeks, 6 months and 1 year after the laser procedure.

this study derives from a clinical observation that laser treated eyed with pxf glaucoma may have a similar long-term response rates when either alt or slt is performed. some authors have considered that there is a risk of iop elevation in the immediate post laser period with alt or slt as a complication to be related to denser angle pigmentation (20,48). (46) no long-term analysis comparing response rates of both laser treatments in these types of patients has been done. primary objective is to determine which laser therapy has more iop lowering effect as primary or adjunctive treatment in eyes diagnosed with ocular hypertension and glaucoma associated to pxf. response rates will be compared between groups at long-term. secondary objective is to determine the relationship between the type of laser therapy performed and angle pigmentation, number of applications, and amount of energy used with age, number and type of medication used post laser and phakic status.

Eligibility criteria:
inclusion criteria: * only patients with clinical evidence of unilateral or bilateral open angle pseudoexfoliation ocular hypertension (iop \> 22mmhg) or glaucoma (evidence on humphrey 30-2 or goldmann of nerve fiber layer damage) with uncontrolled iop, over 18 years of age, and are willing to participate in the study will be included. if increased iop is bilateral then the worst eye will be treated. exclusion criteria: * patients will be excluded if they have evidence of any glaucoma other than pseudoexfoliative open angle, if the trabecular meshwork cannot be seen in 360 degrees, if they had previous laser therapy alt or slt, if they have advanced visual field defect (split fixation or a scotoma within 10 degrees fixation), taking any systemic or topical steroids, have had any previous ocular surgery (glaucoma or cataract extraction included) or laser within the previous six months, if they are monocular patients, if they have any corneal disease precluding the angle evaluation and treatment, or if they had ocular trauma.

Keywords: pseudoexfoliation glaucoma ocular hypertension slt selective laser trabeculoplasy (slt) argon laser trabeculoplasty (alt)
a single-arm phase ii study of post-transoral robotic surgery (tors) alone to the primary tumor site and selective neck dissection (snd) followed by adjuvant radiation therapy (+/- chemotherapy) to the regional nodes for advanced stage, human papilloma virus (hpv) positive, oropharyngeal cancer

Conditions: Oropharyngeal Cancer

Summary: to determine 2-year local (primary tumor site) control and toxicity rates in patients receiving adjuvant rt post-tors, omitting the primary tumor bed, in patients with completely resected, hpv-positive scca of the oropharynx. to determine acute and long-term toxicity rates in patients receiving adjuvant rt post-tors, omitting the primary tumor bed, in patients with completely resected, hpv-positive scca of the oropharynx.


Eligibility criteria:
inclusion criteria: * patients 18 years or older histologically confirmed diagnosis of squamous cell carcinoma of the oropharynx, stage iva, p16-positive on immunohistochemistry pathologic t1 or t2 disease, resected with negative margins ( 2mm) pathologic n2a, n2b, or n2c disease ecog performance status 0-1 * patients must sign an informed consent document that indicates they are aware of the investigational nature of the treatment in this protocol as well as the potential risks and benefits - - - ability to understand and the willingness to provide written informed consent exclusion criteria * prior radiation therapy to the head and neck prior chemotherapy within the past 5 years presence of t3 or t4 disease presence of close (2 mm) or positive margins pni on tors resection of the primary cancer presence of n0 or n1 disease in neck dissection presence of distant metastatic (m1) disease * uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, connective tissue disease or psychiatric illness/social situations that would limit compliance with study requirements.

Keywords: t1-2 n2 m0, stage iva scca oropharynx negative for pni, negative surgical margins
evaluation of gluma desensitizer in post-treatment sensitivity in posterior composite

Conditions: Sensitivity, Tooth

Summary: to evaluate the effect of gluma desensitizer in controlling immediate post-treatment sensitivity in posterior occlusal composite restorations.

the primary objective of this study is to observe the effect of gluma desensitizer application in controlling the post-treatment sensitivity in posterior occlusal composite restoration in molar teeth using 2 adhesive bonding strategies. the secondary objective is to evaluate the difference in the post-treatment sensitivity on application of gluma desensitizer either prior to or after acid etching. the different adhesive gluma desensitizer application groups are randomly divided into 6 groups, 1. total etch control group (no gluma desensitizer application) 2. total etch group gluma (kulzer gmbh, germany) desensitizer application prior to acid etching 3. total etch group gluma (kulzer gmbh, germany) desensitizer application after acid etching 4. self etch control group (no gluma desensitizer application) 5. self etch group gluma (kulzer gmbh, germany) desensitizer application prior to acid etching 6. self etch group gluma (kulzer gmbh, germany) desensitizer application after acid etching

Eligibility criteria:
inclusion criteria: * occlusal cavitated caries in maxillary and mandibular first and second molars exclusion criteria: * occlusal caries with axial or proximal extension * teeth with periodontal treatment within last three months * teeth with cracks * teeth to be taken as abutment for prosthesis * patients with psychiatric treatment * patients in orthodontic treatment or going to need orthodontic treatment * patients under dentin hypersensitivity or using desensitizer treatment * patients not willing for post treatment follow up * patients having any other teeth with pain or sensitivity symptoms * caries excavation with pulp exposure and post treatment sensitivity due to occusal interference in restoration
anterior vs posterior procedures for cervical spondylotic myelopathy: prospective randomized clinical trial

Conditions: Cervical Spondylotic Myelopathy

Summary: there is no difference in surgical outcomes for patients suffering from cervical spondylotic myelopathy treated with anterior decompression and fusion or posterior cervical laminoplasty.

cervical spondylotic myelopathy (csm) is a syndrome consisting of symptoms and signs of cervical spinal cord compression caused by chronic degenerative changes of the cervical spine. csm is the most serious and disabling condition of cervical spondylosis. natural history studies showed that most of the csm patients have a progressive deterioration course and no spontaneous regression occurs. it is suggested that the patients with moderate to severe csm should be operated as early as possible before neurological deficits are too pronounced. although there are many options available for the surgical treatment of cervical spondylotic myelopathy, the choice of surgical approach for csm is still a controversial issue. most of the surgeons select the surgical approach based on the number of levels involved and the alignment of the spine. anterior procedure is generally recommended for patients with compression of less than 3 levels or in patients with kyphotic alignment, while posterior decompression is suggested for three or more levels of compression. retrospective clinical study however has shown that both anterior and posterior surgeries could produce comparable results. there is no scientific data based on randomized, prospective clinical studies comparing the various surgical alternatives. the existing information does not clearly favor any one single approach or operative option. since anterior and posterior surgeries carries different risks, it is important to identify the most appropriate surgical procedure that is supported by evidence rather than just by surgeons preference. the objective of this study is to compare the long-term clinical outcome of anterior approach versus posterior approach in the treatment of cervical myelopathy caused by degenerative disease of the cervical spine.

Eligibility criteria:
inclusion criteria: * patients with transverse lesion type of cervical myelopathy caused by cervical spondylosis requiring surgery. * involved levels limited to 1, 2 and 3 continuous levels exclusion criteria: * radiculomyelopathy * cervical kyphosis * cervical myelopathy caused by high energy trauma * female \> 70 years old or patients with severe osteoporosis * high anaesthetic risk * cervical myelopathy other than transverse type * cervical myelopathy caused by ossification of posterior longitudinal ligament or inter-vertebral disc herniation.

Keywords: cervical spondylotic myelopathy anterior decompression and fusion cervical laminoplasty
observational study of alna® (tamsulosin) in patients with benign prostatic hyperplasia (bph)

Conditions: Prostatic Hyperplasia

Summary: the objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of alna® (tamsulosin) for patients with bph (benign prostatic hyperplasia).


Eligibility criteria:
inclusion criteria: * indication for the treatment with alna according to its summary of product characteristics (spc) exclusion criteria: * patients fulfilling one of the general or specific contraindications listed in the alna spc, particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency cannot be included in the study
efficacy of hypochlorous acid as a postoperative wound antiseptic

Conditions: Wound Healing

Summary: the aim was to examine the effectiveness of hypochlorous acid on postoperative wound healing in 24 systemically healthy gingivectomy participants aged 12-30. the participants were divided into 3 groups as hypochlorous acid group, chlorhexidine group and saline group and their wound healing was evaluated on the 1st, 3rd and 7th days.

the aim of this study was to investigate the effectiveness of hypochlorous acid on postoperative wound healing in 24 participants aged 12-30 who underwent gingivectomy involving the 6 anterior teeth of the upper or lower jaw with chronic inflammatory gingival overgrowth. the participants were divided into 3 groups as hypochlorous acid group, chlorhexidine group and saline group and were called for control on the 1st, 3rd and 7th days to evaluate wound healing. periodontal indexes, visual analog scale (vas), h2o2, plaque staining agent test, and histological analyzes were used to evaluate wound healing. the data were analyzed statistically.

Eligibility criteria:
inclusion criteria: * gingival overgrowth affecting at least six teeth symmetrically in the mandibular or maxillary anterior area * no attachment and bone loss * 7 days before the surgery, full-mouth plaque index (pi) \< 25% and a full-mouth gingival bleeding index (gbi) \< 25%. * the keratinized tissues surrounding the teeth are at least 2 mm wide. exclusion criteria: * smoking or alcohol use * patients who have undergone systemic antimicrobial therapy and surgical procedures within the last 3 months * pregnancy or lactation * immunodeficiency or immunosuppressive drug therapy

Keywords: gingival overgrowth gingivoplasty gingivectomy hypochlorous acid chlorhexidine